Kabiven Peripheral

Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin, the active ingredients in Kabiven Peripheral, are an amino acid solution presented as an intravenous formulation for parenteral nutrition use. It supports protein synthesis, essential metabolic functions, and nitrogen balance in patients who cannot receive enteral feeding.

GNH USA supplies Kabiven Peripheral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology clinics worldwide, ensuring quality and regulatory compliance across markets. The company also provides comprehensive logistics and regulatory support for global distribution.

Kabiven Peripheral, an amino acid solution for parenteral nutrition, is employed to support patients with insufficient oral or enteral intake.

- Inadequate oral/enteral intake: provides essential and non‑essential amino acids to maintain nitrogen balance and support protein synthesis. - Peri‑operative period: supplies amino acids to aid tissue repair and reduce catabolism during surgical recovery. - Critical care patients: delivers intravenous amino acids to meet metabolic demands of severely ill individuals requiring parenteral nutrition.

Kabiven Peripheral may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Hyperglycemia: elevated blood glucose levels, especially in diabetic patients. - Electrolyte disturbances: alterations in sodium, potassium, or calcium concentrations. - Infusion site reactions: erythema, pain, or phlebitis at the catheter site. - Nausea or vomiting: gastrointestinal discomfort during or after infusion. - Mild metabolic alkalosis: slight increase in blood pH. - Increased blood urea nitrogen: transient rise reflecting amino acid metabolism.

Serious or Rare Side Effects: - Anaphylactic reaction: severe hypersensitivity requiring immediate medical intervention. - Severe hyperosmolarity: high solute concentration leading to circulatory stress. - Hepatic dysfunction: abnormal liver enzyme elevations. - Metabolic acidosis: significant drop in blood pH. - Thrombophlebitis: clot formation with vein inflammation. - Life‑threatening electrolyte imbalances: such as hyperkalemia or severe hypocalcemia.

When using Kabiven Peripheral, clinicians should observe specific precautions to ensure patient safety. - Renal impairment: monitor serum creatinine and adjust infusion rate as needed. - Hepatic dysfunction: assess liver function tests before and during therapy. - Electrolyte disorders: regularly check sodium, potassium, and calcium levels. - Hyperglycemia risk: closely monitor blood glucose in diabetic or pre‑diabetic patients. - Pregnancy and lactation: consider use only if potential benefit outweighs possible risk to mother and fetus. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Kabiven Peripheral can interact with other medications, affecting electrolyte balance or metabolic control.

Major Interactions (Avoid): - High‑dose potassium chloride: may cause dangerous hyperkalemia when combined. - Concurrent parenteral nutrition solutions: risk of precipitation and incompatibility. - Loop diuretics: can exacerbate electrolyte shifts and volume depletion.

Moderate Interactions (Monitor Closely): - Insulin therapy: may require dose adjustments due to glucose load from amino acids. - Corticosteroids: can increase protein catabolism, potentially reducing efficacy. - Renal replacement therapy: may alter amino acid clearance, necessitating dosage review.